Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Multiple Sclerosis Research Study Participants to Contribute from Smartphones

By Novartis Pharmaceuticals Corp. | August 25, 2017

Novartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones.

Novartis this week announced the launch of a mobile research study for people with multiple sclerosis (MS) that collects data via their smartphone, without the need for clinic visits. The study, Evaluation of Evidence from Smart Phone Sensors and Patient-Reported Outcomes in Participants with Multiple Sclerosis (elevateMS), is designed to collect sensor-based data from physical tasks and symptoms.

It aims to improve understanding of the daily challenges patients with MS can have and to uncover new potential measurements of treatment effectiveness through real-time data collection from participants in their everyday life.

The elevateMS study, which was developed in partnership with Sage Bionetworks, uses a mobile application that was built on the Apple ResearchKit* platform. This emerging digital smartphone research platform allows study participants to contribute to research from home or on the go. At the same time, it enables researchers to collect data in the participant’s everyday environment. To download the app and enroll in the study, please visit https://itunes.apple.com/us/app/elevatems/id1233909485?ls=1&mt=8.

The mobile app was designed with input from patients, neurologists and advocates. Patients commented on the app’s user interface, what the study should measure, and how the app should track patient activity and disease symptoms.

“As physicians, we always want to know how our patients with MS are doing on the treatments we prescribe,” said Stanley Cohan, M.D., Ph.D., medical director, Providence Multiple Sclerosis Center, Portland, Oregon. “With the elevateMS app, study participants can frequently document their symptoms in a personal health story. In turn, this data may provide researchers with new ways to look at disease progression and treatment effectiveness,” added Dr. Cohan, who serves as a scientific advisor to the study.

The elevateMS study is open to U.S. participants with and without MS who can download the application from the Apple App Store and provide their mandatory informed consent. Participants have a right to leave the study anytime they like. Using smartphones, the elevateMS application will capture participant responses to questionnaires, passive and active sensor-based movement data, and functional performance tasks completed by the participants.

Participants will be able to use the application to view how their data changes over time. Researchers will use data from all participants to understand what it is like to live with MS. The names of participants will be replaced with a random code, so the researchers and study sponsor Novartis won’t know the individual’s identity.

Additional information about the elevateMS study is available at www.elevatems.org.

Novartis is a leader in MS with three approved medications, along with additional investigational therapies in early and late phases of development.

(Source: PR Newswire)

Related Articles Read More >

This is a Hemco marketing image of its MicroFlow self-contained workstation.
Hemco highlights its self-contained workstations
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Moving toward the autonomous lab and what’s possible today
Female worker at pharmaceutical factory operating control panel of the pharmaceutical machine.
How real-time sensors and data-savvy can cut energy waste in pharma
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE